Failure is fairly common in the world of biotech development as companies struggle to bring candidates forward, but the impact those results have on other candidates in development is what is really important to investors. For Xenon, the company is hoping a failure in osteoarthritis pain doesn't affect an ongoing study in neuropathic pain.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?